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The Efficacy of Warm Compresses in the Treatment of Meibomian Gland Dysfunction
and Demodex Folliculorum Blepharitis
Orla Murphy , Veronica O’ Dwyer, and Aoife Lloyd-Mckernan
School of Physics & Clinical & Optometric Sciences, Dublin Institute of Technology, Dublin, Ireland
ABSTRACT
Purpose: To investigate and compare the effect of warm compresses on meibomian gland dysfunction
and Demodex folliculorum blepharitis.
Methods: Forty-two subjects (13 males, 29 females; mean age of 56.45 years) enrolled and completed
the two-month warm compress treatment study. Three warm compress therapies were compared: Warm
face cloth, MGDRx EyeBag® and OPTASETM Moist Heat Mask. Subjects attended for four visits: baseline,
two weeks, four weeks, and eight weeks. Subjective symptoms, osmolarity, non-invasive tear break-up
time, ocular surface staining, Schirmer I test, meibum expressibility and clarity, and eyelash manipulation
and epilation to assess for the presence of Demodex folliculorum, were measured at each visit.
Results: Meibomian gland dysfunction, based on a composite score of meibum quality and expressibility,
reduced significantly with the MGDRx EyeBag® and the OPTASETM Moist Heat Mask (p < .05). There was no
significant difference in efficacy for treatingmeibomian gland dysfunction between the two devices (p = .29).
No improvement in meibomian gland dysfunction was detected with the warm face cloth. Only the
OPTASETM Moist Heat Mask significantly reduced the quantity of Demodex folliculorum over eight-weeks
of treatment (p = .036, only baseline to week eight significant p = .008). Symptoms and ocular surface
staining improved significantly in all three groups (p < .05). There was no significant change observed in
osmolarity, non-invasive tear break-up time or Schirmer I test within each group (p > .05, respectively).
Conclusion: The MGDRx EyeBag® and the OPTASETM Moist Heat Mask exhibited superior efficacy in treating
signs and symptoms of meibomian gland dysfunction, compared to the use of a warm face cloth, over the
eight-week period. The OPTASETM Moist Heat Mask demonstrated dual therapeutic abilities, treating both
meibomian gland dysfunction and Demodex folliculorum blepharitis. Repeated application of heat for the
treatment ofmeibomian gland dysfunctionmay continue to present a good home-remedy option for patients.
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The meibomian glands are a group of holocrine glands found in
the upper and lower eyelids. They consist of parallel rows of
small secretory acini arranged around a larger central duct which
opens onto the eyelid margin.1,2 The role of the meibomian
glands is to supply meibum to the ocular surface: to prevent
evaporation of the tear film, provide a smooth refractive corneal
surface for better vision, and act as a barrier to microbial agents
and organic matter such as dust.3–6 Disruption to this supply,
often through terminal duct obstruction or changes in glandular
secretion, can interfere with the homeostasis of the tear film and
ocular surface; leading to inflammation and subsequent symp-
toms of discomfort.5,7
The eyelash follicles are located within the eyelids, anterior to
the meibomian glands. Because of their close proximity to one-
another, anomalies of the eyelash follicles and the meibomian
glands are often seen in combination with each other.8–11 One
such anomaly, is the inhabitation of the eyelashes and meibomian
glands by the common ecto-parasites:Demodex folliculorum (DF)
andDemodex brevis (DB).Demodex folliculorum tend to reside in
clusters in the eyelash follicles12–14 and have beenmost commonly
linked with anterior blepharitis12,15–19 while DB generally burrow
deeper into themeibomian glands and have beenmore commonly
associated with meibomian gland dysfunction (MGD).13,20–22
The association between DB infestation and severe MGD and
keratitis has been described in the literature.10,23 Although DF are
generally associated with anterior blepharitis and infestation of the
eyelash follicles, the prevalence of DF in the eyelash follicles of
MGD patients has been reported to vary between 46.5% to
85%.24,25 Treatment in the form of lid scrubs, targeted at reducing
the quantity of both DB and DF, has shown improvement in
ocular surface health and patient symptoms.10,23
The mainstay treatment recommended for DF and DB infes-
tation is lid scrubs with diluted quantities of tea tree oil.26–28While
lid scrubs have been indicated as an early treatment option for
patients with mild MGD, warm compress therapy remains the
principal treatment for MGD.29 In order for warm compresses to
be effective, heat must pass through the anterior eyelid structures,
including the eyelashes, to warm and melt thickened meibum
within themeibomian glands. Themelting temperature of normal
meibum is approximately 32°C, and is higher at approximately
35°C in obstructed glands with altered secretions.29,30 Therefore, it
is recommended that for warm compresses to be effective at
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treating MGD, they need to heat the inner eyelid to a temperature
of ≥ 40°C.31 However, bothDB andDF prefer lower temperatures,
and Zhao et al. have shown that temperatures above 37°C are
damaging to DF.32 Higher temperatures cause death by protein
coagulation and denaturation, and eventual paralysis of the DF
nervous system.32Murakami et al. have shown that although there
is variety in inner eyelid temperatures achieved by different warm
compresses, most methods do manage to reach outer eyelid
temperatures of ≥ 40°C.33 Hence, as heat from thewarm compress
passes through the eyelash follicles to heat the inner eyelid, it could
potentially have the effect of killing the DF within the eyelash
follicle. Intense pulsed light used for treating MGD has shown
therapeutic ability for Demodex infestation.34
Traditionally, home based warm compresses were carried
out using a warm face cloth.29,35 However, this method has its
limitations, including poor heat retention,36 and inconveni-
ence leading to reduced compliance.29 Over the years, more
patient-friendly warm compresses have become available,
such as the MGDRx EyeBag® (The EyeBag® Company,
Halifax, UK) and the OPTASETM Moist Heat Mask (Scope
Ophthalmics Ltd., Dublin, Ireland). While both warm com-
presses are principally very similar; they are heated in
a microwave, and a single heating is required to provide
10 minutes of therapy; there are fundamental differences
between them. The OPTASETM Moist Heat Mask contains
HydroBeadTM Technology, which absorbs moisture from the
air, and when heated, releases it to provide a moist heat. The
moist heat therapy helps to soften eyelash debris in patients
with anterior blepharitis, and restores moisture to the eye and
surrounding area, in conjunction with improving meibum
flow, tear film quality and reduced tear film evaporation. By
contrast, the MGDRx EyeBag® is filled with flax seed and
provides a dry heat when applied to the eyelids.
Manufacturers recommend it for relief of, including but not
limited to; MGD, blepharitis, dry eye syndrome, and rosacea.
Their efficacy in the treatment of Demodex blepharitis has not
previously been investigated.
The aim of the current study was to assess the therapeutic
effect of these common home-based warm compresses on DF
infestation in MGD patients.
Materials and methods
Study design
This was a single-centre, interventional, randomised, controlled,
examiner masked clinical trial. The study was conducted under
the Tenets of Helsinki Declaration of Human Studies37 and
approved by the Technological University Dublin Research
Ethics Committee. All subjects were recruited through the
National Optometry Centre, Technological University Dublin,
Ireland’s private and student optometry clinics. Written
informed consent was obtained from all subjects prior to enrol-
ment. Subjects were examined for the presence of MGD and DF
and were given a warm compress to use for 10 minutes twice
a day for two weeks, followed by 10 minutes once a day for the
remaining six weeks. The frequency and duration of treatment
was based around MGDRx EyeBag® and OPTASETM Moist
Heat Mask manufacturers guidelines on instructions for use,
10 minutes twice a day for the first two weeks and then reduce
frequency. Instructions were kept consistent for all treatment
groups. As DF have a lifespan of two-three weeks,38 an eight
week treatment duration was decided to ensure treatment was
provided over generations of DF.
Study participants
A priori analysis for repeated measures ANOVA (α = 0.05,
1-β = 0.80, effect size = 0.5: 3 groups, 2 measurements) was
used to calculate the minimum sample size required. Effect
size was calculated from the mean and standard deviation of
the difference of DF presentation on lash manipulation and
microscopic examination from previous data collected on 428
eyelashes: 0.84/1.59 = 0.52. The minimum total sample size
required was 33 subjects; 11 subjects per group. Fifty subjects
in total were enrolled between April 2017 and May 2018.
Subjects were eligible to participate if they were; ≥ 18 years
of age and had ≥ G1 MGD based on meibomian gland
expression according to the diagnostic subcommittee of the
International Workshop on Meibomian Gland Dysfunction.39
Subjects were excluded if they; wore contact lenses, were
pregnant, had a systemic disease or were using topical/sys-
temic medication known to affect the eyes, presented with
ocular disease (with the exception of MGD and blepharitis),
were currently using MGD/blepharitis treatment or had used
such treatment within the last six months, or had ocular
surgery in the last six months.
Study procedures
Subjects attended the National Optometry Centre for four
visits in total: Baseline, week two, week four, and week
eight. All examinations were conducted in the same room,
at the same time of day (±30 minutes), by the same examiner
(author OM). Examinations were conducted in the same
order at each visit, from least invasive to most invasive.40,41
Subjects completed a validated, modified OSDI symptom
questionnaire,42 and were scored from 0–100, with higher
numbers indicating increased severity of symptoms. The
modified OSDI questionnaire was chosen as it includes ques-
tions that are more specific to Demodex blepharitis: itchy eyes.
Modification of existing questionnaires has been previously
recommended in order to increase the sensitivity of the ques-
tionnaire in diagnosing MGD and blepharitis,39 and modifi-
cation of the OSDI questionnaire has been previously used in
Demodex studies.28,43 Non-invasive tear break-up time
(NITBUT) was measured using the Medmont E300 Corneal
Topographer (Medmont International Pty Ltd., Victoria,
Australia). An average of three measurements was recorded
for each eye. Tear osmolarity was measured using the TearLab
Osmolarity System (TearLab Corporation, San Diego,
California). One measurement was taken from each eye. An
inter-eye difference of > 8 mOsm/L indicates tear film
instability.44 A cut-off threshold measurement of > 308
mOsm/L is most sensitive to differentiating between normal
and mild to moderate dry eye subjects.44,45 The eye with the
highest tear osmolarity measurement at baseline was chosen
as the study eye, and this eye was used for all data analysis.
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Ocular surface staining was assessed using fluorescein dye
(Fluorets; Chauvin Pharmaceuticals, United Kingdom) and
a yellow wrattan filter, and graded using the Oxford
Grading System.46 Corneal, and nasal and temporal bulbar
conjunctival staining were each graded individually on a 6
point scale (0–5 for each location, 0 indicating no staining, 5
indicating severe staining). Results were then combined to
provide a composite score (0–15) for each eye.46 Schirmer
I test (without anaesthesia) (Tear Flo; HUB Pharmaceutical,
United Kingdom) was performed to measure subjects tear
secretion. Subjects were asked to close their eyes,47 and the
score was measured as the wetting length in mm/5 min.
Subjects were considered to have ‘dry eye’ if found to have
three or more of the following six parameters; OSDI ≥ 12,
osmolarity ≥ 308 mOsm/L, tear osmolarity variance ≥
8 mOsm/L, NITBUT < 10 secs, ocular surface staining ≥3
Oxford score or Schirmer I score ≤ 5 mm/5 min.
Slit-lamp bio-microscopy (Topcon SL-D701, Topcon Medical
Systems Inc., Dublin, Ireland) was conducted to examine the
meibomian glands in accordance with the diagnostic subcommit-
tee of the International Workshop on Meibomian Gland
Dysfunction39; firm digital pressure was applied to the eyelid
margins and the number of glands expressible, from the central
eight glands, was graded on a four-point scale (0 = all glands
expressible, 1 = 3–4 glands expressible, 2 = 1–2 glands expressible,
3 = no glands expressible). The quality of meibum secreted was
graded on a four-point scale (0 = clear, 1 = cloudy, 2 = cloudy with
particulate, 3 = thick like toothpaste). As recommended, compo-
site scores derived from the expression of both upper and lower
eyelids was generated and used for statistical analysis.39 Lastly, one
eyelash from each eyelid was examined for the presence of DF
through eyelash rotation and epilation on the slit-lamp bio-micro-
scope. Examiners chose to examine one eyelash per eyelid at each
visit as subjects were being examined over four visits. Many of the
subjects were older, some with chronic MGD and blepharitis, and
therefore had a reduced number of eyelashes. Hence, many sub-
jects were not keen on having any eyelashes removed at each visit.
In an effort to increase subject participation and retention, it was
decided to only remove one eyelash from each lid at each visit.
Eyelashes were chosen in accordance with the modified Coston
method.48 Briefly, the modified Coston method recommends
selectively choosing eyelashes in an effort to maximise potential
of finding DF.48 As such, eyelashes with cylindrical dandruff or
mis-directed eyelashes (possibly due to a damaged follicle) were
chosen. In the absence of cylindrical dandruff or mis-directed
eyelashes, eyelashes were chosen from the central region of the
eyelid. In keeping with the modified Coston method, alcohol and
fluorescein were used to facilitate imaging of the mites on micro-
scopic examination. A limitation of the modified Coston method
is that it can lead to undercounting; through DF remaining within
the follicle after the eyelash has been removed. It has been estab-
lished previously that DF can be detected through eyelash
rotation,49 and a recent study has also shown that the quantity
of DF detected on rotation of the eyelash within the follicle is
a better indicator of severity of infestation.50 As such, both quan-
tity of DF found on eyelash rotation and on microscopic exam-
ination have been examined in this study. Each eyelash was
rotated in situ, using sterile forceps, to examine for the presence
of DF within the follicle. The number of DF tails seen emerging
from the eyelash follicle was counted. The same eyelash was then
epilated and examined on a microscope slide using the modified
Coston method,48 and the number of DF present was recorded.
Similar to MGD, a composite score was derived for each eye from
quantities found on upper and lower eyelids and used for statis-
tical analysis. The percentage of subjects with DF in each group
was also determined. Positive DF infestation was defined as the
presence of ≥ 1 DF detected on either eyelash manipulation or
microscopic examination. Based on work by Randon et al. the
proportion of DF was further classified into non-pathogenic (≤ 3
mites) and pathogenic infestation (>4 mites) per eye.22 Quantities
of Demodex folliculorum detected on eyelash manipulation were
used for this classification.
The intra-class correlation co-efficient (ICC) was deter-
mined to examine the agreement in pre-treatment results
between the right and left eyes for each participant. A two-
way mixed analysis with absolute agreement and 95% confi-
dence intervals was conducted.51 Quantity DF (ICC: 0.71),
MGD Grade (ICC: 0.93), osmolarity (ICC:0.68), NITBUT
(ICC:0.82), ocular surface staining (ICC: 0.77), Schirmer I test
(ICC: 0.91) and dry eye (ICC:0.67). Values of less than 0.5
indicate ‘poor’ agreement, between 0.5 and 0.75 ‘moderate’
agreement, between 0.75 and 0.9 ‘good’ agreement, and greater
than 0.90 ‘excellent’ agreement.51 As recommended, data ana-
lysis was conducted on one eye only for each participant.52 As
all correlations were between moderate to excellent, either eye
was considered eligible for selection. Therefore, the eye selected
for data analysis was chosen based on the higher tear osmolar-
ity value at baseline. This is in keeping with previous studies
and osmolarity measurement guidelines.44,45,53
Following enrolment, subjects were randomly allocated one
of three treatments to use at home: Face cloth (Group 1, con-
ventional treatment: n = 12), MGDRx EyeBag® (Group 2, dry
heat: n = 16), OPTASETM Moist Heat Mask (Group 3, moist
heat: n = 14). In keeping with manufacturers’ guidelines, each
subject was given an instruction leaflet and was required to use
the treatment for 10 minutes twice a day for the first two weeks.
Frequency of compresses was reduced to 10 minutes once a day
from weeks three to eight. Subjects in Group 1 were instructed
to pour 200 ml of boiled water into a bowl and allow it to cool
for 10 minutes before beginning treatment. This created
a water temperature ranging from 50°C to 39°C over the 10-
minute treatment time (tested using a HYGIPLAS Easy tem-
perature pocket catering thermometer and porcelain bowl).
Subjects’ were then required to re-heat the face cloth every
two minutes, by immersing it in the same bowl of cooled,
boiled water; to maintain temperature at therapeutic
levels.31,54 Groups 2 and 3 were instructed to heat their com-
press in the microwave for 15–30 seconds depending on the
power of their microwave, as per manufacturers’ guidelines.
Statistical analysis
Statistical analysis was performed using SPSS IBM (ver. 25.0).
Normality was measured using Shapiro-Wilk statistical test.
Repeated measures Analysis Of Variance (ANOVA) with
Bonferroni post-hoc analysis was used to analyse repeated
measures within each group over time for parametric data.
Friedman’s test was used to analyse repeated measures, within
CURRENT EYE RESEARCH 565
each group, across different visits for non-parametric data.
With Friedman’s test, post-hoc analysis was conducted, where
appropriate, using Wilcoxon signed ranks test for pairwise
comparisons, adjusted using Bonferroni correction
(α = 0.05/number of comparisons: α = 0.05/6 = 0.0083).55
One way ANOVA with Bonferroni post-hoc analysis was used
to analyse data between continuous variables at baseline and
at different visits for parametric data. Kruskal Wallis (K-W)
was used for non-parametric data. With K-W, post-hoc ana-
lysis was conducted, where appropriate, using Mann
Whitney-U test for pairwise comparison, adjusted using
Bonferroni correction (α = 0.05/number of comparisons:
α = 0.05/3 = 0.0167).55 Parametric data was expressed as
mean ± standard deviation, non-parametric data was
expressed as median and inter-quartiles. Post-hoc analysis
was only conducted on significant findings. A p-value < 0.05
was considered statistically significant, with the exception of
Bonferroni adjusted post-hoc analysis as described above.
Results
Fifty subjects were enrolled between April 2017 and
May 2018. Attrition rate was 16%. Four subjects withdrew
from the study, without any known adverse events and were
lost to follow up. Two subjects discontinued as they felt their
symptoms were worsening. A further two were removed from
data analysis as their records were incomplete. Following
attrition, 42 subjects (13 males and 29 females) with a mean
age of 56.45 ± 16.71 years completed the two-month warm
compress treatment study. At baseline, an overall proportion
of 57.1% DF was found, with a mean quantity of 2.31 (range
0–13) and 1.14 (range 0–9) mites on lash rotation and micro-
scopic examination respectively. There was no significant
difference in age (Group 1: 59.08 ± 14.27, Group 2:
58.13 ± 15.83, Group 3: 52.29 ± 19.78, K-W: p = .754) or
quantity of DF on either lash rotation or microscopic
examination (K-W: p = .784 and p = .847) between the
three groups before treatment.
Dry eye disease
Applying the dry eye classification previously outlined in
Study Procedures, the proportion of subjects with dry eye in
each group, at each visit, is shown in Figure 1. No significant
change in proportion of subjects with dry eye was detected in
any of the three treatment groups post-treatment (Group 1–3:
Friedman’s p = .362, p = .768 and p = .284, respectively).
Demodex folliculorum analysis
Table 1 displays the quantity of DF at each visit for each treat-
ment group. Figure 2 illustrates the change in quantity of DF
detected on eyelash rotation within each group over the eight
weeks.Within treatment analysis showed that the quantity of DF
dropped significantly over the duration of the study in Group 3
(OPTASETM Moist Heat Mask) (Friedman’s p = .036). Post-hoc
pairwise comparisons using Wilcoxon signed ranks test, with
alpha level adjusted for Bonferroni correction, showed only the
change from baseline to week eight to be significant (median:
1.50, IQR: 0–4.25 versus median: 0, IQR: 0–1.5; WSR p = .008).
There was no significant change in DF quantity in Group 1
(Warm Face Cloth) or Group 2 (MGDRx EyeBag®) over the
eight weeks (Friedman’s p = .884 and p = .661, respectively).
Between treatments analysis did not show any significant differ-
ence between the treatments over the eight weeks (K-W p > .05,
Table 1).
The median and interquartile values, for quantity of DF
detected on microscopic examination at each visit, for each
group, are also shown in Table 1. In contrast to results
observed on eyelash rotation, there was no significant change
in DF quantity detected on microscopic examination over
time in each group (Friedman’s p > .05) or between treat-
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Figure 1. Proportion of subjects with dry eye disease in each warm compress treatment group at each time point.
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The overall proportion of subjects with DF in each group
at baseline was: Group 1–66.67%, Group 2–50.00%, and
Group 3–57.14%. There was no significant difference found
between the groups at baseline (K-W p = .609). This reduced
to an overall proportion of: Group 1–58.33%, Group
2–25.00% and Group 3–50.00% after eight weeks. Table 2
shows the proportion of subjects with pathogenic and non-
pathogenic infestation for each treatment group, at each point
in time. Group 3 demonstrated the largest reduction in patho-
genic infestation of the three groups (−14.29%, n = 2). This
likely accounted for why the OPTASETM Moist Heat Mask
(Group 3) appeared to have the greatest overall effect on
quantity of DF using the eyelash manipulation technique.
The MGDRx EyeBag® (Group 2) appeared to have the great-
est effect on the overall proportion of DF (−25.00%, n = 4).
However, no significant difference in proportion of DF was
found between the groups at week eight (K-W p = .185).
Furthermore, no significant difference in proportion of patho-
genic and non-pathogenic DF infestation was found within
the groups over the eight weeks: Group 1 (Friedman’s
Table 1. Demodex folliculorum quantity (median and interquartile range) before and after treatment.
Variable Time
Group 1 (Warm Face Cloth)
N = 12
Group 2 (MGDRx Eye Bag®)
N = 16
Group 3 (Optase Moist Heat MaskTM)
N = 14
Quantity Demodex folliculorum (n)
Lash Rotation
BL 0 (IQR: 0–5.25) 0.50 (IQR: 0–2) 1.50 (IQR: 0–4.25) KW p = .778
W2 0.50 (IQR: 0–1.75) 0 (IQR: 0–2) 0 (IQR: 0–1) KW p = .693
W4 0.50 (IQR: 0–3.50) 0 (IQR: 0–3) 0 (IQR: 0–4) KW p = .907
W8 0.50 (IQR: 0–8.50) 0 (IQR: 0–0) 0 (IQR: 0–1.50) KW p = .282
F p = .868 F p = .641 F p = .036*
Quantity Demodex folliculorum (n)
Microscope
BL 0 (IQR: 0–1.75) 0 (IQR: 0–1) 0 (IQR: 0–2.75) KW p = .843
W2 1 (IQR: 0–2.75) 0 (IQR: 0–0) 0 (IQR: 0–0) KW p = .018
W4 0.50 (IQR: 0–1) 0 (IQR: 0–0) 0.50 (IQR: 0–1.75) KW p = .323
W8 0 (IQR: 0–1.75) 0 (IQR: 0–0) 0 (IQR: 0–1) KW p = .485
F p = .719 F p = .665 F p = .179
B: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight, IQR: interquartile range. Statistical Tests Applied: KW Kruskal-Wallis, F Friedman’s. α = 0.05 significant.
*Significant results highlighted in bold.
Post – hoc analysis: Wilcoxon signed ranks test pairwise comparison with Bonferroni adjusted 
correction applied (α ≤ 0.008 significant). B: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. 
*Significant results highlighted in bold.
Post - hoc Face Cloth MGDRx EyeBag® OPTASETM Moist 
Heat Mask
B – W2 0.271 0.730 0.023
B – W4 0.677 0.523 0.313
B – W8 0.527 0.344 0.008*
W2 – W4 0.496 0.713 0.500
W2 – W8 0.173 0.713 1.000
W4 – W8 0.831 1.000 0.125
Figure 2. Box plot illustrating the change in quantity of Demodex folliculorum at two, four, and eight weeks, with each treatment.
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p = .998), Group 2 (Friedman’s p = .176) and Group 3
(Friedman’s p = .486).
MGD grade
The box plot in Figure 3 demonstrates change in MGD grade
after treatment, for each group. There was a significant reduc-
tion in MGD grade with time for each treatment (Friedman’s
p = .008, Figure 3). Post hoc analysis using Wilcoxon signed
ranks test pairwise comparisons, with adjusted Bonferroni
corrected alpha level, revealed significant improvements
from baseline to week eight in Group 2 (median: 2, IQR:
1–2 versus median: 1, IQR: 0–2; WSR p = .008), and improve-
ments from baseline to week eight (IQR: 1–2 versus median:
1, IQR: 0–1; WSR p = .002) and week two to week eight
(median: 1, IQR: 1–2 versus median: 1, IQR: 0–1; WSR
p = .003) in Group 3. There was no significant difference
found between the treatments at any time point over the
eight weeks (K-W p > .05).
Modified OSDI symptoms
Figure 4 illustrates a box plot of the change in modified OSDI
symptom score for each treatment group over time. There was
a significant reduction in OSDI symptom score with time for
each treatment (repeated ANOVA p = .038, p = .023 and
p = .022 for Groups 1–3 respectively, Table 3). As can be
seen from Figure 4, the greatest reduction in symptoms
appears to be in Group 2 and Group 3. Post hoc analysis
with Bonferroni pair-wise comparison revealed; only the
reduction in symptoms from baseline to week two and base-
line to week eight (p = .033 and p = .008 respectively) in
Group 2, and reduction in symptoms from baseline to week
two and baseline to week eight (p = .013 and p = .047 respec-
tively) in Group 3, were found to be significant (Figure 4).
There was no significant difference in modified OSDI symp-
tom score between the treatments at any time point over the
eight weeks (ANOVA p > .05, Table 3).
Clinical signs of dry eye
Figure 5 illustrates a box plot of the change in osmolarity
values for each group at each visit. There was a significant
reduction in osmolarity for subjects in Group 3 over the eight
weeks (repeated ANOVA p = .014, Table 3). Bonferroni post-
hoc analysis showed that this was significant from baseline to
week four only (p = .017, Figure 5). There was no significant
change in osmolarity detected for subjects in Groups 1 and 2
at any stage over the eight weeks (repeated ANOVA p > .05,
Table 3). Overall, repeated measures of ANOVA taking treat-
ment into consideration as a between subjects’ factor, showed
no significant change in osmolarity overtime (p = .107).
The presence of tear film instability, with an inter-eye
difference of ≥8 mOsm/L, was also measured for each subject
(Table 3). At baseline, the presence of tear film instability for
each group was as follows: Group 1–83.33%, Group 2–40.00%
and Group 3–71.44%. After eight weeks tear film instability
had reduced in Group 1 (41.67%) and Group 3 (64.22%) but
had increased slightly in Group 2 (60.00%). None of these
changes were found to be significant within each group over
time (Friedmans p > .05) or between each group at any point
in time (K-W p > .05).
There was a significant reduction in ocular surface staining
over time for each treatment (Friedman’s p = .043, p = .007
and p = .035 for Groups 1–3 respectively, Table 3). Post hoc
analysis using Wilcoxon signed ranks test pairwise compar-
isons, with Bonferroni corrected alpha level, revealed; only
a reduction in staining from week two to week eight in Group
2 (mean: 1.71, range 0–8; median: 1, IQR: 0–2 versus
mean:0.33, range 0–2; median: 0, IQR: 0–0.75; WSR
p = .006), and week two to week eight in Group 3 (mean:
1.77, range 0–9; median: 1, IQR: 0–3.25 versus mean:0.50,
range 0–4; median: 0, IQR: 0–0.75; WSR p = .008), were
found to be significant. There was no significant difference
in ocular surface staining between the treatments at any time
point over the eight weeks (K-W p > .05).
Mean NITBUT and Schirmer I scores for each treatment
group, at each time point, can be seen in Table 3. There was
no significant change in NITBUT, or Schirmer I score, over
time in each group (Friedman’s p > .05), or between treat-
ments (K-W p > .05).
Discussion
Demodex brevis is most commonly associated with MGD, how-
ever, it has been established in the literature that DF andMGD are










Group 1: Face Cloth
(n = 12)
Baseline 33.33 (n = 4) 33.33 (n = 4) 33.33 (n = 4) 66.67% (n = 8)
Week Two 33.33 (n = 4) 41.67 (n = 5) 25.00 (n = 3) 66.67% (n = 8)
Week Four 33.33 (n = 4) 41.67 (n = 5) 25.00 (n = 3) 66.67% (n = 8)
Week Eight 41.67 (n = 5) 25.00 (n = 3) 33.33 (n = 4) 58.33% (n = 7)
Difference (Baseline to Week Eight) +8.34% (n = 1) −8.34% (n = −1) 0.00% (n = 0) −8.14% (n = −1)
Group 2: MGDRx EyeBag®
(n = 16)
Baseline 50.00 (n = 8) 31.25 (n = 5) 18.75 (n = 3) 50.00% (n = 8)
Week Two 62.50 (n = 10) 12.50 (n = 2) 25.00 (n = 4) 37.50% (n = 6)
Week Four 62.50 (n = 10) 25.00 (n = 4) 12.50 (n = 2) 37.50% (n = 6)
Week Eight 75.00 (n = 12) 12.50 (n = 2) 12.50 (n = 2) 25.00% (n = 4)
Difference (Baseline to Week Eight) +25.00% (n = 4) −18.75% (n = −3) −6.25% (n = −1) −25.00% (n = −4)
Group 3: OptaseTM Moist
Heat Mask
(n = 14)
Baseline 42.86 (n = 6) 28.57 (n = 4) 28.57 (n = 4) 57.14% (n = 8)
Week Two 50.00 (n = 7) 35.71 (n = 5) 14.29 (n = 2) 50.00% (n = 7)
Week Four 50.00 (n = 7) 28.57 (n = 4) 21.43 (n = 3) 50.00% (n = 7)
Week Eight 50.00 (n = 7) 35.71 (n = 5) 14.29 (n = 2) 50.00% (n = 7)
Difference (Baseline to Week Eight) +7.14% (n = 1) +7.14% (n = 1) −14.29% (n = −2) −7.14% (n = −1)
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also connected.11,24,25 At present lid scrubs are themain treatment
recommended for Demodex blepharitis,56 and warm compress
therapy the mainstay treatment for MGD.29 The potential thera-
peutic effect of heat for treating DF infestation has been previously
shownusing intense pulsed light therapy.34However, to the best of
the authors’ knowledge, this is the first study to investigate the
effect of heat therapy using warm compresses on DF infestation.
This study has demonstrated that the use of OPTASETM Moist
Heat Mask may have a double therapeutic effect, treating MGD
and reducingDF in combination. Over the eight weeks,moist heat
therapy from the OPTASETM Moist Heat Mask significantly
reduced the quantity of DF detected using the eyelash rotation
technique. No significant change was noted with the moist heat
from the warm face cloth, or the dry heat from the MGDRx
EyeBag®. The reason for this is unknown; it may be related to
the compresses ability to achieve a higher treatment temperature.
For the warm compresses to be effective at treating MGD, they
need to heat the inner eyelid to a temperature of ≥ 40°C.31
Manufacturers of OPTASETM Moist Heat Mask report tempera-
tures from 50°C to 41°C for the 10-minute duration of therapy.57
By comparison, theMGDRx EyeBag® only achieves temperatures
of 46°C dropping to 39°C after 5 minutes.58 Likewise, the warm
face cloth does not retain its heat for longer than two minutes
without needing to be re-heated in the cooled boiled water.31,54
This could affect the overall therapeutic temperature achieved by
the face cloth with respect to treating DF infestation.
While the MGDRx EyeBag® did not appear to have
a significant impact on DF quantity, the proportion of DF




W2 0 (0 – 0.75) 0 (-1 – 0) 0 (0 – 0)
W4 -1 (-1 – 0) -0.5 (-1 – 0) 0 (-1 – 0)
W8 -1 (-1.75 - 0) -1 (-1 – 0) -1 (-1 – 0)
p value F p = 0.008* F p = 0.002* F p = 0.002*
Post - hoc Face Cloth MGDRx EyeBag® OPTASETM Moist 
Heat Mask
BL – W2 0.414 0.527 1.000
BL – W4 0.035 0.035 0.180
BL – W8 0.030 0.008* 0.002*
W2 – W4 0.021 0.025 0.414
W2 – W8 0.018 0.024 0.003*
W4 – W8 0.414 0.157 0.058
X represents the mean change in MGD Grade. Post – hoc analysis: Wilcoxon signed ranks 
test pairwise comparison with Bonferroni adjusted correction applied (α ≤ 0.008 significant). 
BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant results highlighted 
in bold.
Figure 3. Box plot illustrating change in MGD Grade after two, four, and eight weeks with each treatment.
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infestation did improve considerably (by 25%) in Group 2.
Although there was no significant difference in the mean
quantity of DF at baseline between the three treatment
groups; Group 2 had the lowest quantity and lowest propor-
tion of subjects with pathogenic infestation of the three
groups at baseline. Therefore, the authors believe that these
lower numbers of DF within Group 2 affected the compresses
ability to demonstrate significant changes over time. A post-
hoc power calculation was conducted on the data, and a low
power (1 – β = 0.26) was detected; which would have affected
the power and significance of the results. If one was to assume
baseline values were equal, then data at week eight may show
that both the MGDRx EyeBag® and OPTASETM Moist Heat
Mask had similar quantities, potentially even favouring the
MGDRx EyeBag®; suggesting that the MGDRx EyeBag® also
had similar therapeutic abilities for treating DF blepharitis.
However, due to the limitations outlined above, it is not
currently possible to directly compare the efficacy of
OPTASETM Moist Heat Mask to the MGDRx EyeBag® from
the study results. Future research that focusses on pathogenic
infestation (to ensure higher quantities of DF per subject),
would help reduce any limitations caused by lower numbers
of DF.
Similarly, no significant change was detected in quantity of
DF using the traditional modified Coston method,48 for any
of the warm compresses studied. As can be seen from the
current study, the quantity of DF detected whilst rotating the
eyelash in-situ was significantly greater than that observed on
microscopic examination (paired t-test p = .014, p = .015 and
p = .007 for baseline, week four and week eight respectively).
No significant difference was observed in both techniques in
week two, where overall a low quantity of DF was detected.
The authors postulate that the low quantity of DF detected in
week two may be as a result of subjects using the warm
compresses for 10 minutes twice a day. After two weeks,
subjects reduced treatment time to 10 minutes once a day,
and the quantities of DF appeared to increase again slightly.
Thus, suggesting a direct correlation between length of heat
therapy and therapeutic effect. The authors speculate that the
lack of significant results found using the modified Coston
method was due to the limitations of the method.
Undercounting, results in reduced quantities of DF, which
affects the compresses ability to demonstrate change, as out-
lined previously.
Hyperosmolarity is considered one of the hallmark signs
of dry eye disease and ocular surface inflammation.59 In
MGD, availability of meibum to the ocular surface is com-
promised either through reduced secretion (possibly due to
poor expressibility, or severe meibomian gland dropout), or
a poor quality secretion; thus causing increased tear
Table 3. Dry eye parameters; Modified OSDI symptom score (mean ± SD), Osmolarity (mean ± SD), tear film instability (%), NITBUT (median and IQR), ocular surface
staining (median and IQR), Schirmer I (median and IQR), before and after treatment.
Variable Time Group 1 Group 2 Group 3
Modified OSDI Score (0–100) BL 24.21 ± 15.27 39.81 ± 23.21 39.01 ± 20.34 Ap = .123
W2 22.05 ± 15.29 27.40 ± 19.29 24.70 ± 18.87 Ap = .688
W4 15.71 ± 7.86 23.03 ± 19.55 23.65 ± 19.89 Ap = .412
W8 15.14 ± 12.75 16.67 ± 13.07 26.52 ± 17.15 Ap = .098
RA p = .038* RA p = .023* RA p = .022*
Osmolarity (mOsm/L) BL 304.17 ± 18.10 303.53 ± 9.55 318.86 ± 13.44 Ap = .008*
W2 301.27 ± 17.47 304.71 ± 12.98 310.27 ± 16.46 Ap = .413
W4 303.92 ± 18.88 299.93 ± 13.68 305.92 ± 14.69 Ap = .688
W8 305.50 ± 18.82 303.07 ± 11.91 312.86 ± 13.37 Ap = .194
RA p = .596 RA p = .863 RA p = .014*
Instability (%) BL 83.33% 40.00% 71.44% X2p = .059
W2 54.55% 50.00% 63.67% X2p = .912
W4 50.00% 53.33% 66.67% X2p = .777
W8 41.67% 60.00% 64.22% X2p = .530
CQ p = .224 CQ p = .872 CQ p = .786
Staining
(0–15)
BL 1 (IQR: 0–2) 1 (IQR: 0–1.75) 0 (IQR: 0–2) KWp = .978
W2 0 (IQR: 0–2) 1 (IQR: 0–2) 1 (IQR: 0–3.25) KWp = .030*
W4 0 (IQR: 0–0.75) 0 (IQR: 0–1) 0 (IQR: 0–1) KWp = .720
W8 0 (IQR: 0–0.75) 0 (IQR: 0–0.75) 0 (IQR: 0–0.75) KWp = .953
F p = .043* F p = .007* F p = .035*




























F p = .954 F p = .870 F p = .600




























F p = .209 F p = .934 F p = .570
BL: Baseline, W2: Week Two, W4: Week Four, W8: Week Eight. Statistical Tests Applied: A ANOVA, RA Repeated Measures ANOVA, KW Kruskal-Wallis, F Friedman’s, X2
Chi-squared, CQ Cochran’s Q. α = 0.05 significant.
*Significant results highlighted in bold.
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evaporation and, one would expect, an increase in
osmolarity.60 However, there are conflicting reports in the
literature.60–63 In the current study, subjects in Group 3
(OPTASETM Moist Heat Mask) demonstrated a significant
improvement in osmolarity overtime. However, subjects in
Group 3 had a greater osmolarity at baseline in comparison
to subjects in the other two groups, which is likely to have
had an effect on the overall reduction in osmolarity values
detected in Group 3. Similar to the current study, Kim et al.
reported a significant improvement in osmolarity post-treat-
ment in subjects who had a pre-treatment osmolarity of
>307 mOsm/L, and no significant improvement in osmolar-
ity post-treatment in subjects who had an osmolarity of
<307 mOsm/L pre-treatement.64 The authors concluded
that heat treatment with a thermal pulsation device was
effective at improving osmolarity in subjects with abnormal
osmolarity values, but did not have an effect on those with
normal tear osmolarity.64 By comparison, Godin et al. found
that treatment of MGD with a thermal pulsation device on
a cohort of subjects with Sjogrens syndrome caused an
initial increase in osmolarity two months after treatment
(305.2 vs. 315.6, p = .026), but no significant increase
one year after treatment (305.2 vs 311.0, p = .86).61 Group
1 and Group 2 in the current study had similar low pre-
treatment osmolarity values. However, neither the heat ther-
apy from the warm face cloth or the MGDRx EyeBag®
caused an increase in osmolarity values after two months
of treatment. Giannaccare et al. analysed the performance of
an ocular surface work-up using modern automated non-
invasive measurements for diagnosing MGD.62 The authors
looked at non-invasive methods such as NITBUT, osmolar-
ity, lipid layer thickness and non-contact meibography and




BL – W2 1.000 0.033* 0.013*
BL – W4 0.266 0.078 0.064
BL – W8 0.054 0.008* 0.047*
W2 – W4 0.673 1.000 1.000
W2 – W8 0.687 0.100 1.000
W4 – W8 1.000 0.464 1.000
X illustrates mean change in modified OSDI score. Post – hoc analysis: Bonferroni (α ≤ 0.05 
significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant 
results highlighted in bold.
Figure 4. Box plot illustrating change in modified OSDI symptom score for each treatment group, at each visit.
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found significant differences between MGD subjects and
controls for NITBUT, OSDI symptom score and meibomian
gland loss.62 However, they found no significant difference
in osmolarity values between the two groups.62 Similar to
the current study, and the study by Godin et al.,61
Giannaccare et al. found a low mean osmolarity value
among their MGD subjects (303.5 ± 9.8 mOsm/L).62 The
lack of significance found in the current and previous stu-
dies, may be related to the low osmolarity found among
MGD patients.61,62 It has been proposed that MGD disease
may not cause an increase in tear osmolarity, as the disease
alone may not be sufficient enough to alter the homeostatic
control in many subjects.62,63 In the current study, the
authors have been unable to find an explanation for the
higher osmolarity values observed in Group 3. Subjects in
Group 3 were not significantly older, or more symptomatic,
and did not have a significantly greater quantity of DF,
MGD, ocular surface staining, or reduced TBUT or tear
secretion at baseline. Furthermore, repeated measures of
ANOVA, with treatment as a between subjects’ factor,
showed no significant change in osmolarity overtime.
Therefore, the authors propose that the increased osmolarity
value observed at baseline in Group 3 may be happenstance
with regards to the current study.
Heat therapy has been shown to increase the availability of
meibum to the tear film and ocular surface, helping to improve
the stability of the tears, and thus, increase tear break-up time
(TBUT).54,58,65–67 In the current study, although changes were
Post - hoc Face Cloth MGDRx EyeBag® OPTASE
TM Moist 
Heat Mask
BL – W2 1.000 1.000 0.220
BL – W4 1.000 1.000 0.017*
BL – W8 1.000 1.000 0.980
W2 – W4 1.000 1.000 1.000
W2 – W8 1.000 1.000 1.000
W4 – W8 1.000 1.000 0.699
X denotes mean change in osmolarity. Post – hoc analysis: Bonferroni (α ≤ 0.05 significant). 
BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant results highlighted in bold.
Figure 5. Box plot illustrating change in osmolarity values for each treatment group at each visit.
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not significant, the MGDRx EyeBag®, the dry warming device,
demonstrated the greater increase in NITBUT of the three
compresses examined. These results are in keeping with Arita
et al. who found that only dry warming devices were able to
significantly improve the oily tear film layer, and therefore
TBUT.65 In the same study, no improvement was observed
after the repeated use of a hot towel compress, and the authors’
concluded that moisture on the surface of the eyelid skin may
possibly give rise to evaporative cooling; thus limiting the favour-
able effects of warming.65 None of the compresses used in the
current study demonstrated significant increases in NITBUT.
This lack of significance may be attributed to the differences in
measurement techniques and timings of measurements post-
treatment. In previous studies, TBUT has been measured inva-
sively using fluorescein,67,68 or non-invasively using a TearScope
Plus.58,66 The invasive nature of the fluorescein dye has been
shown to alter the tear film and affect the natural TBUT.69,70
Although the TearScope Plus is a non-invasive method, it is
a subjective measurement, and relies on the examiner observing
the first noticeable break in the fine line pattern. Conversely, in
the current study NITBUT was measured using the automated
Medmont E300 Corneal Topographer, which has demonstrated
good repeatability with a high sensitivity and specificity for
diagnosing moderate to severe dry eye disease.53 Thus, all mea-
surements were objectively taken by the instrument, which is
more sensitive to small tear film instabilities. Furthermore, in
previous studies, many TBUT measurements have been taken
immediately after, 5–10 minutes after, or up to 1 hour after heat
therapy has been applied.58,65,66 In the current study, subjects
applied the warm compresses at home in the evenings.
Therefore, there was a much greater time gap between last
warm compress and time of measurement. Although immediate
effect of treatment has not been established in the current study,
the results do demonstrate the ‘real’ effect of each treatment on
subjects’ tear film and ocular surface.
A limitation of the current study was that subjects were
applying the heat therapy at home. As a result, it was not
possible to measure the temperature of the compress each
time it was used. Insufficient lid warming of warm compresses
have been noted previously in the literature.71,72 Although all
subjects were given written instructions, it is possible that
subjects may not have heated the compress sufficiently, or
did not complete the full 10-minute therapy requested of
them. In an attempt to monitor compliance, at each aftercare,
subjects were asked to report on how many evenings and for
how long they used the warm compress as instructed. The
overall reported compliance at the end of the study was
83.74%: 77.92% warm face cloth, 86.81% MGDRx EyeBag®,
and 85.45% OPTASETM Moist Heat Mask. Poor compliance is
a problem with examining efficacy of treatments, thus it
would be preferable to have 100% compliance and treatment
provided in-house by the examiner. As the warm face cloth
group had the lowest compliance, it cannot be ruled out that
this impacted on the ability of the compress to demonstrate
any significant results for treating MGD or DF blepharitis.
However, the use of warm compresses in the current study is
potentially a better indicator of warm compress use in ‘real
world’ environments.
The MGDRx EyeBag® and the OPTASETM Moist Heat
Mask significantly reduced the presence of MGD over the
duration of the study. Although some improvement in
MGD was seen with the warm face cloth, these changes
were not found to be significant. Furthermore, the warm
face cloth compress had to be re-dipped every 2 minutes, as
it lost its heat quickly. Therefore, compresses that can be
heated once and used for 10 minutes at a time are much
more convenient for patient use. There was also a higher
rate of attrition in the warm face cloth group than either of
the other two groups, and overall compliance was lowest in
this group. The authors feel that this was due to the incon-
venient nature of the treatment. As such, if patients will not
be compliant with a treatment, for example due to inconve-
nience, then it won’t matter whether it works in a clinical lab
scenario if it won’t be used correctly in the ‘real-world’.
The microwaveable compresses, MGDRx EyeBag® and
OPTASETM Moist Heat Mask, exhibited a greater ability to
treat MGD, reduce symptoms and reduce ocular surface
staining, in comparison to the more ‘traditional’ warm face
cloth compress. The OPTASETM Moist Heat Mask appears to
demonstrate an ability to provide dual treatment to patients
with MGD and Demodex blepharitis. The MGDRx Eyebag®
demonstrated a possible ability to provide dual treatment for
MGD and Demodex blepharitis, however, further research is
required to confirm.
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